EyePoint’s bid to compete with Eylea falls flatnews2026-08-17T15:38:40+00:00August 17th, 2026|Endpoints News|
Biotech’s reverse merger renaissance poised to continuenews2026-08-17T15:12:10+00:00August 17th, 2026|Endpoints News|
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertunews2026-08-17T14:53:46+00:00August 17th, 2026|Endpoints News|
Summit, Akeso’s ivonescimab shows smaller benefit with longer follow-up in Chinanews2026-08-17T14:48:39+00:00August 17th, 2026|Endpoints News|
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse mergernews2026-08-17T14:36:05+00:00August 17th, 2026|Endpoints News|
Celcuity awaits FDA review for second factory to launch cancer drugnews2026-08-17T13:19:34+00:00August 17th, 2026|Endpoints News|
Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositisnews2026-08-17T10:51:24+00:00August 17th, 2026|Endpoints News|
AstraZeneca cans late-stage volrustomig trial after lung cancer setbacknews2026-08-17T10:47:39+00:00August 17th, 2026|Endpoints News|
Trump’s MMR order; LSD drug clears Phase 3 test; and morenews2026-08-15T10:00:56+00:00August 15th, 2026|Endpoints News|
Cytokinetics brings patent suit against Bristol Myers, escalating rivalrynews2026-08-14T17:44:45+00:00August 14th, 2026|Endpoints News|
